Design of multi-target D-Ala-D-Ala ligase ligands
Design of multi-target D-Ala-D-Ala ligase ligands
批准号:
7979299
负责人:
Judith Varady Hobrath
金额:
$24.94万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2012-06-30
关键词:
Adverse effectsAffinityAgonistAlanineAlanine RacemaseAnabolismAnti-Bacterial AgentsAntibioticsAntimycobacterial AgentsBindingBinding SitesBiochemical ProcessBiological AssayCell WallCellsCessation of lifeComputer SimulationCrude ExtractsCycloserineCytolysisD-Alanine-D-alanine ligaseDataDevelopmentDipeptidesDivalent CationsDrug DesignEffectivenessEnterococcusEnzymesEpidemicEscherichia coliEssential GenesExtreme drug resistant tuberculosisFundingGenus MycobacteriumGrowthHumanLateralLeadLigand BindingLigandsMulti-Drug ResistanceMutagenesisMycobacterium tuberculosisN-MethylaspartateNebraskaOsmotic PressureOutcomePeptidesPeptidoglycanPharmaceutical PreparationsPhosphotransferasesPhysiological ProcessesPopulationProcessProteinsProtocols documentationReactionReportingResistanceResolutionSalmonella typhimuriumScreening procedureSiteStaphylococcus aureusStructureTexasTherapeutic AgentsToxic effectTuberculosisUniversitiesValidationVertebral columnanalogantimicrobial drugassay developmentbactericidebasecrosslinkdesigndrug developmentenantiomerenzyme mechanisminorganic phosphatemicroorganismmycobacterialneurotransmissionnovelnovel therapeuticspathogenpublic health relevancereceptorresistant strainscaffoldstemtuberculosis treatment
中文摘要
描述(由申请人提供):结核分枝杆菌是当今的一种主要流行病,每年在全球造成800万新病例和300万人死亡。迫切需要通过新机制起作用的新型抗结核药物,以便与现有药物联合进行更有效的治疗,并治疗近年来出现的多重耐药菌株。细菌细胞壁含有肽聚糖,提供抵抗外部渗透压的能力。肽聚糖生物合成的靶向步骤是开发新型抗菌药物的一个有吸引力的机制。一个重要的步骤是合成d -丙烯酰- d -丙氨酸二肽(D-Ala-D-Ala),这是形成肽聚糖和交联肽聚糖链所必需的。催化这一过程的酶是d -丙氨酰- d -丙氨酸连接酶(DDl)。由于D-Ala-D-Ala的合成是细菌生长的必要过程,而且DDl在人体中没有等同物,因此DDl是新抗生素的极好靶点。我们已经应用了基于硅结构的方法来鉴定和分析DDl ATP和底物位点结合配体,使用在HTS筛选中显示出抗结核分枝杆菌H37Rv活性的化合物组和显示与DDl结构相似的激酶结合配体。我们建议在前半部分完善和验证DDl结合预测方案,并利用这些方案来识别和分析基于已知有效抗结核靶点支架的化合物,以对抗DDl的活性。
英文摘要
DESCRIPTION (provided by applicant): Mycobacterium tuberculosis is a major epidemic today, causing 8 million new cases and 3 million deaths yearly world-wide. New anti-tubercular drugs that act through novel mechanisms are urgently needed for more efficacious treatments in combination with existing drugs and for treating multi-drug resistant strains that emerged in recent years. The bacterial cell wall contains peptidoglycan that provides resistance from external osmotic pressure. Targeting steps of peptidoglycan biosynthesis is an attractive mechanism for new antibacterial agents. An essential step is the synthesis of D-Alanyl-D-Alanine dipeptide (D-Ala-D-Ala) that is required for the formation of peptidoglycan and for cross-linking peptidoglycan strands. The enzyme catalyzing this process is D-Alanyl-D-Alanine ligase (DDl). DDl is an excellent target for new antibiotics since synthesis of D-Ala-D-Ala is an essential process for bacterial growth and furthermore there is no human equivalent to DDl. We have applied an in silico structure based approach to identify and assay DDl ATP and substrate site binding ligands using sets of compounds that have shown activity against M. tuberculosis TB H37Rv in HTS screening and kinase binding ligands that show structural similarities to DDl. We propose to refine and validate DDl binding prediction protocols in the first half of the proposed effort and utilize these to identify and assay compounds based on known scaffolds of valid anti-tubercular targets for activity against DDl.
PUBLIC HEALTH RELEVANCE: New anti-tubercular drugs that act through novel mechanisms are urgently needed for more efficacious treatments of tuberculosis and for treating multi-drug resistant strains that recently emerged. In this proposal we have apply an in silico structure based approach to identify and assay novel potent DDl binders and multi- TB target ligands.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Design of multi-target D-Ala-D-Ala ligase ligands
-
批准号:8098979
-
项目类别:
-
资助金额:$32.03万
-
财政年份:2010
-
负责人:Judith Varady Hobrath
-
依托单位:
Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
-
批准号:7687911
-
项目类别:
-
资助金额:$27.78万
-
财政年份:2008
-
负责人:Judith Varady Hobrath
-
依托单位:
Development of Opioid Receptor Models for Rational Design of Bifunctional Ligands
-
批准号:7512750
-
项目类别:
-
资助金额:$27.26万
-
财政年份:2008
-
负责人:Judith Varady Hobrath
-
依托单位:
海外基金